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Summary
Objectives: To determine the effects of two drugs, N-monomethyl-L-arginine (L-NMMA) and N-acetylcysteine (NAC), on interleukin-1
(IL-1), nitric oxide (NO) and prostaglandin E2 (PGE2) production by human chondrocytes. The effect of aceclofenac (ACECLO), a
non-steroidal antiinflammatory drug (NSAID), was also examined.
Methods: Human chondrocytes were enzymatically isolated from osteoarthritic knee cartilage and then maintained in culture in suspension
for 48 h in the absence or in the presence of lipopolysaccharide (LPS) (10 g/ml), L-NMMA (0.5 mM), NAC (1 mM) or ACECLO (6 · 10−6 M).
IL-1 and PGE2 productions were quantified by specific immunoassays. Nitrite was measured in the culture supernatants by a
spectrophotometric method based upon the Griess reaction. Cyclooxygenase-2 (COX-2), inducible NO synthase (iNOS) and IL-1 gene
expressions were quantified by transcription of mRNA followed by real time and quantitative polymerase chain reaction. COX-2 protein
expression was analysed by Western blot.
Results: LPS markedly increased the expression of IL-1, iNOS and COX-2 genes. In parallel, NO2 and PGE2 amounts found in the culture
supernatants were significantly enhanced whereas IL-1 was immunologically undetectable. The addition of L-NMMA (0.5 mM) fully blocked
LPS-induced NO production but greatly increased PGE2 production, suggesting a negative effect of NO on PGE2 synthesis. Inversely, NO
production was stimulated by NAC while PGE2 production was not affected. Interestingly, NAC increased the IL-1 and iNOS mRNA levels
but did not significantly modify COX-2 mRNA expression. L-NMMA did not significantly affect the expression of IL-1, iNOS and COX-2. The
amount of COX-2 protein did not change in the presence of the antioxidants. Finally, ACECLO fully blocked the production of PGE2 by
chondrocytes without affecting the levels of COX-2 mRNA.
Conclusions: The stimulation of IL-1, NO and PGE2 production by LPS is differentially controlled by reactive oxygen species (ROS). In fact,
L-NMMA and NAC have different mechanisms of action on the regulation of NO and PGE2 productions. L-NMMA fully inhibits NO but
increases PGE2 production whereas NAC up-regulates NO but does not modify PGE2 synthesis. The stimulating effect of L-NMMA on PGE2
production is not controlled at the transcriptional level. These findings suggest that antioxidant therapy could have different effects according
to the oxygen radical species targeted. © 2002 OsteoArthritis Research Society International. Published by Elsevier Science Ltd. All
rights reserved.
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NO is a gaseous free radical, which is transformed to nitrite
and nitrate in the presence of oxygen. NO is synthesized
through L-arginine oxidation by a family of NO synthases. It
rapidly reacts with superoxide anions (O ·2) to form peroxy-
nitrite (OONO−) which is a strong oxidant. It is well
accepted that chondrocytes possess a NADPH oxidase
and produce both ROS and NO1,2. In vitro, ROS and NO
productions are strongly stimulated by IL-1, which is a key
cytokine in the pathogenesis of arthritis3. Nitric oxide is
presented as a catabolic agent since it was demonstrated547that intraarticular injection of L-NIL (n-iminoethyl-L-lysine),
a selective inhibitor of inducible nitric oxide synthase,
reduced the progression of cartilage erosion in an exper-
imental osteoarthritic dog model4. In vitro, the inhibition of
endogenous NO production by L-NMMA, another well
established NO synthase inhibitor, led to the suppression of
IL-1 stimulating effects on metalloproteases5 and partially
reversed the IL-1 inhibitory effect on glycosaminoglycan
synthesis by chondrocytes6. Furthermore, NO inhibits IL-1
receptor antagonist (IL-1ra) production by chondrocytes, a
mechanism possibly responsible for the enhancement of
IL-1 biological activity7.
Although there is a general agreement that NO is
involved in cartilage destruction, the literature is unclear
about the role played by NO in the initiation and progres-
sion of synovial membrane inflammation. NO was originally
identified as the endothelium-derived relaxing factor with
potential proinflammatory effects, including increase of
vascular permeability, enhancement of PGE2 synthesis8–10
and the induction of catabolic cytokines like IL-1 and
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SHORT TERM SUSPENSION CULTURE OF HUMAN CHONDROCYTES
Cartilage specimens were obtained from the knees of
eight donors shortly after death (four males and four
females) with the mean age of 49 (47–52) years old, being
excised from the superficial and medium layers and avoid-
ing the calcified layer. Upon dissection, femoral and patellar
articular surfaces were evaluated for the severity of the
macroscopic cartilage lesions using a personal scale. Four
different grades were considered: 0, normal white cartilage
on all areas examined; I, presence of yellow-gray area with
some superficial fibrillations on one or more articular sur-
faces; II, irregular surface with deep fibrillations on one or
more articular surfaces; III, ulcers penetrating to subchon-
dral bone on one or more articular surface. Four out of the
eight cartilage samples collected showed lesion of grade III
and four cartilage samples had lesion of grade I. Each
culture was run with chondrocytes from a single patient.
The cartilage slices were cut into small fragments and
then subjected to sequential enzymatic digestions with
hyaluronidase, pronase and collagenase as previously
described13. The cells were then filtered through a nylon
mesh (70 m), washed three times, counted (1.106 cells/
ml) and resuspended in 1 ml of adequate culture medium:
DMEM without red phenol (Biowhittaker, Brussels,
Belgium) supplemented with 10 mM HEPES, penicillin
(100 U/ml), streptomycin (0.1 mg/ml) and 1% of ITS+ (ICN,
Doornveld, Belgium). ITS+ is a culture supplement contain-
ing in 1 ml: 0.625 mg of insulin, 0.625 mg of transferrin,
0.625 g of selenious acid, 125 mg of bovine serumalbumin (BSA) and 0.535 mg of linoleic acid. The cells
recovered after collagenase digestion of the tissue were
95% viable (trypan blue test). Cells were then kept in
culture medium for 48 h in order to eliminate in vivo
contamination with drugs that the donors may have taken
before death.
After this washout period, cells (1 · 106 cells/ml in culture
medium) were seeded in 15 ml polypropylene Falcon tubes
and maintained under agitation on a gyratory shaker
(100 rpm) in a 95% air/5% CO2 environment. Chondro-
cytes were cultured for 48 h in the absence or in the
presence of LPS (10 g/ml, serotype 026:B6; Sigma-
Aldrich, Bornem, Belgium) and with or without L-NMMA
(0,5 mM; Calbiochem, San Diego, U.S.A.) NAC (1 mM);
Sigma-Aldrich, Bornem, Belgium) or ACECLO (6 · 10−6 M;
Prodesfarma, Spain). ACECLO was first dissolved in
N,N-dimethylformamide (DMF, Sigma-Aldrich, Bornem,
Belgium), and then diluted in culture medium to achieve the
required concentration. The final concentration of DMF was
0.1%. A similar amount of the vehicle was added to the
controls. Cells and supernatant were then separated by
centrifugation (1000 rpm; 5 min). Other chemicals were of
the purest commercial grade available.NITRIC OXIDE ASSAY
NO production was determined by quantifying its derived
product nitrite in conditioned medium using a spectro-
photometric method based on the Griess reaction19. Briefly,
150 l of conditioned culture medium or sodium nitrite
(NaNO2) standard dilutions were mixed with 100 l of
Griess reagent (0.5% sulfanilanide, 0.05% naphtyl ethylen-
ediamine dihydrochloride, 2.5% H3PO4) and incubated for
5 min at 37°C. The limit of detection was 2 M of nitrite.
Before adding the Griess reaction, nitrate was converted to
nitrite by treating sample with nitrate reductase (0.2 U/mL,
Roche, Brussels, Belgium)20. The absorption was
measured at 540 nm.PGE2 RADIOIMMUNOASSAY
PGE2 level was determined in conditioned culture
medium according to a previously described radioimmuno-
assay (RIA)21 using a polyclonal antiserum, obtained from
rabbit. The 3H-labeled PGE2 was purchased from New
England Nuclear (Brussels, Belgium) and the standard
molecule PGE2 from Sigma-Aldrich (Bornem, Belgium).
PGE2 was measured in triplicate in a 100-l aliquot of each
sample. After 48 h of incubation at 4°C, free antigen was
separated from antibodies-antigen complex by charcoal
precipitation and centrifugation (20 min at 1000 g, 4°C).
The supernatant was counted by liquid scintillation. Intra-
and interassay coefficients of variation were 6 and 10%,
respectively. The recovery of known amounts of PGE2
added to the culture medium was satisfactory (90 to 97%
for the amounts of PGE2 ranging from 2500 to 312 pg/ml).
The limit of detection of the RIA was 20 pg/ml.IL-1 ASSAYS
IL-1 production by chondrocytes was assayed in the
culture media by two different enzyme amplified sensi-
tivity immunoassays (EASIA) designed by RD System
(Abingdon, U.K.) and by Genzyme (Cambridge, U.S.A.).
The assays were directly performed in the culture mediaTNF. Further evidence that NO may be antiinflammatory
under certain circumstances is provided by its ability to
down-regulate PGE211–14, IL-6 and IL-8 production by
chondrocytes and liver kupffer cells13,15 and to suppress
the production of O ·2 by neutrophils through a direct action
upon NADPH-oxidase16. These conflicting results obtained
with NO synthase inhibitor could be explained by the fact
that intracellular signalling pathways are very sensitive to
intracellular fluctuation of ROS levels. This hypothesis
gains strong support from the finding that the two well
studied nuclear transcription factors, NF-kB and AP-1, are
activated when intracellular ROS are increased or
decreased, respectively17. These factors are involved in
rapid induction of gene transcription in response to a
variety of pathogenic conditions, specifically chronic inflam-
mation. Another explanation could be that NO reactivity
could be strongly different according to its ability to react
with other oxygen species to form new oxidative molecules.
In fact, NO interacts easily with O ·2 to form not only the
most potent peroxynitrite but also derivative active free
radicals such as peroxynitrous acid, hydroxyl radical and
nitrogen dioxide18.
This complex interdependent regulation of NO, IL-1 and
PGE2 creates a dilemma for pharmacological intervention
of NO. In pathological context, such as arthritis where both
inducible NOS and COX-2 are activated, therapeutical
strategies focused on regulating COX activity by NO may
be of some benefit.
In view of these observations, this study was designed to
investigate the effects of antioxidant molecules on IL-1
and PGE2 productions by human chondrocytes and then to
identify the regulatory role played by NO or derived reactive
species.
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two assays were 1 and 0.1 pg/ml, respectively.DNA ASSAY
Chondrocyte DNA content was directly correlated to the
cell number of each culture. DNA content was measured in
the cell pellet extracts using a fluorimetric method. This
measurement ensures elimination of result variations due
to the different number of chondrocytes22.REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION
(RT-PCR)
RNA was isolated by a single step guanidinium
thiocyanate-phenol-chloroform method. Cells (3 · 106)
were lysed using TRI REAGENT (Sigma-Aldrich, Bornem,
Belgium) and the samples were processed following the
manufacturer’s protocol. RNA (2 g) was reverse tran-
scribed in a volume of 30 l containing 1× RT buffer,
10 mM DTT, 1 mM dNTPs, 500 ng oligo(dT)15 primer,
140 U M-MLV reverse transcriptase and 40 U RNaseOUT
(Life Technologies, Merelbeke, Belgium) for 60 min at
37°C. The reaction was halted by an incubation at 95°C for
5 min and by adding 100 l of H2O.
The polymerase chain reaction was carried out in
an automatic DNA thermal cycler (Hybaid, Doornveld,
Belgium). Primer sequences used to amplify the desired
cDNA are as follows: h-actin forward and reverse primers:
5′-GTGGGGCGCCCCAGGCACCA-3′ and 5′-CTCCTTAAT
GTCACGCACGATTTC-3′; hGAPDH forward and reverse
primers: 5′-TTGGTATCGTGGAAGGACTCA-3′ and 5′-
TGTCATCATATTTGGCAGGTTT-3′; hiNOS forward and
reverse primers: 5′-CCATGGAACATCCC AAATAC-3′ and
5′-TCTGCATGTACTTCATGAAGG-3′; hCOX-2 forward
and reverse primers: 5′-TTCAAATGAGATTGTGGGA
AAA-3′ and 5′-AGATCATCTCTGCCTGAGTATCTT-3′; h
IL-1 forward and reverse primers: 5′-TCTCCGACC
ACCACTACAGCA A-3′ and 5′-GGGGAACTGGGCAGA
CTCA A-3′.
The reaction mixture contained 2 l cDNA (equivalent to
30 ng of RNA), 0.5 M sense and antisense primer, 250 M
dNTPs, 1× PCR buffer, 1.5 mM MgCl2 and 1U Taq DNA
polymerase (Life Technologies, Merelbeke, Belgium) in a
final volume of 40 l. The cycle program was set to dena-
ture at 95°C for 45 s, to anneal at 55°C for 45 s, and to
extend at 72°C for 90 s. The number of cycles was selected
in the exponential phase of the amplification curve (20
cycles for -actin, 26 for iNOS, COX-2 and IL-1).
Electrophoresis of the PCR products was performed on
1.5% agarose gels containing 0.1 g/ml ethidium bromide.QUANTITATIVE REAL-TIME PCR
PCR reaction was performed by using the LightCycler-
FastStart DNA master Sybr Green I (Roche Diagnostics,
Brussels, Belgium). This reaction mixture is provided as a
10-fold stock solution containing FastStart Taq DNA polym-
erase, reaction buffer, dNTP mix, 10 mM MgCl2 and SYBR
Green I dye. For each LightCycler PCR, a mastermix of the
following reaction components was prepared in a final
volume of 18 l: 2 l LightCycler-FastStart DNA master
Sybr Green I, 1.6 l of 25 mM MgCl2, 0.5 M sense and
antisense primer. The mastermix was loaded into glass
capillary (Roche Diagnostics, Brussels, Belgium) and 2 lof PCR template was added. The template source was
either 3 ng first-strand cDNA or purified DNA standard.
Amplification was performed with a spectrofluorometric
thermal cycler (LightCycler, Roche Diagnostics, Brussels,
Belgium). After an initial denaturation step at 95°C for
10 min, amplification was performed using 40 cycles of
denaturation (95°C for 15 s), annealing (temperature
gradient: 68°C to 58°C with an increment of 0.5°C per cycle
during 20 cycles, continued by 20 cycles at 58°C, for 5 s)
and extension (72°C for 15 s). For each run, a standard
curve was generated from purified DNA ranging from 106 to
10 copies. To standardize mRNA levels, we amplified
glyceraldehyde-3-phosphate deshydrogenase (GAPDH), a
house-keeping gene as internal control. Normalized gene
expression was calculated as the ratio between sample
and GAPDH cDNA copy number.
After amplification, a final melting curve was recorded by
cooling the PCR mixture to 65°C for 30 s and then slowly
heating it to 95°C at 0.1°C/s. Fluorescence was measured
continuously during the slow temperature rise to monitor
the dissociation of the dsDNA. Specificity of the expected
IL-1, iNOS and COX-2 LightCycler products were
demonstrated by melting curves analysis.
Amplification products performed in the LightCycler were
checked by electrophoresis on 1.5% ethidium bromide
stained agarose gel. The estimated size of the amplified
fragments matched the calculated size.WESTERN-BLOT ANALYSIS
After incubation with the different drugs, chondrocytes
(5 · 106 cells) were washed three times with PBS and lysed
by boiling for 5 min in 150 l of lysis buffer (10 mM Tris-HCl,
pH 7.4, 1% SDS, 0.1 mg/ml PMSF). Equal amounts of
protein (20 g) estimated by bicinchonimic acid reagent
(Pierce, Rockford, U.S.A.) were loaded onto 10% SDS-
polyacrylamide gel and were transferred to nitrocellulose
membrane (Bio-Rad, Nazareth, Belgium). Sheep COX-2
purified enzyme (Cayman Chemical, Ann Arbor, U.S.A.)
was also loaded on the gel as positive control. The mem-
brane was satured with 5% fat-free dry milk in phosphate-
buffered saline (80 mM Na2HPO4, 25 mM NaH2PO4,
100 mM NaCl, pH 7.5) with 1% (v/v) Tween 20 (PBST)
overnight at 4°C. The membrane was incubated with puri-
fied polyclonal rabbit IgG antibody against a peptide corre-
sponding to amino acids 567–599 of human COX-2
(Cayman Chemical, Ann Arbor, U.S.A.) at 1:1000 dilution in
PBST for 1 h at room temperature. The blot was washed in
PBST three times (10 min each). The blot was further
incubated for 1 h at room temperature with goat anti-
rabbit IgG antibody coupled to horseradish peroxidase
(Biosource, Nivelles, Belgium) at 1:20,000 dilution in PBST.
After three washing (10 min) in PBST, the blot was incu-
bated with chemiluminescence substrates (ECL Plus,
Amersham, Rosendaal, The Netherlands) according to the
manufacturer’s instructions. The blot was exposed to a
radiographic film for 15 s.CALCULATION AND STATISTICAL ANALYSIS
The results were expressed as amounts of NO2 plus
NO3 and PGE2 into supernatants per g of DNA. The
mean±standard deviation (S.D.) of each variable was calcu-
lated. A multivariate repeated measures ANOVA model with
calculation of contrast was performed on all of the exper-
iments (MANOVA; SAS system; general linear models).
550 M. Mathy-Hartert et al.: ROS on human chondrocytesFig. 1. Effects of L-NMMA, NAC and ACECLO on the productions of NO2/NO3 and PGE2 by human chondrocytes. Chondrocytes were
cultured for 48 h in the absence (A), (B) or the presence (C), (D) of LPS (10 g/ml) and with or without with L-NMMA (0.5 mM), NAC (1 mM),
L-NMMA (0.5 mM)+NAC (1 mM) or ACECLO (6 · 10−6 M). NO2/NO3 [white columns, (A) and (C)] and PGE2 [hatched columns, (B) and (D)]
concentrations were measured in conditioned culture supernatants and are normalized to the production obtained in the absence of the drug.
Each condition was tested in triplicate. Results are the mean±S.D. of seven experiments performed with cartilage specimens of different
donors. Comparison of mean values was performed by ANOVA analysis. Drug treated groups are significantly different from the untreated
groups: ***P<0.001.
Osteoarthritis and Cartilage Vol. 10, No. 7 551ResultsFig. 2. Effect of L-NMMA, NAC and ACECLO on IL-1, iNOS and COX-2 mRNA levels. Human chondrocytes were cultured for 48 h in the
absence or the presence of LPS (10 g/ml). Co-incubation with L-NMMA (0.5 mM), NAC (1 mM) or ACECLO (6 · 10−6 M) were realized. Total
RNA were isolated and mRNA of IL-1 (A), iNOS (B), COX-2 (C) quantified by real-time RT PCR as described in Materials and Methods. The
mRNA copy numbers were normalized against the corresponding copy number of GAPDH mRNA. Data represent mean±S.D. of triplicate.
Comparison of mean values was performed by ANOVA analysis (drug treated groups are significantly different from the untreated groups:
***P<0.001, **P<0.01).EFFECTS OF L-NMMA, NAC AND ACECLO ON NO AND PGE2
PRODUCTIONS BY HUMAN CHONDROCYTES
Chondrocytes were isolated from seven different donors.
As previously described13, NO and PGE2 synthesis were
significantly stimulated in the presence of LPS. In both
basal and LPS-stimulated conditions the NO and PGE2
productions varied markedly according to the donor consid-
ered. After 48 h of incubation, the mean basal production
of NO2/NO3 and PGE2, calculated on seven different
chondrocyte cultures, were 2.39 nmoles/g DNA/48 h
and 10.41 pg/g DNA/48 h, respectively. LPS increased
NO and PGE productions by mean 2.8 and 7.2 times,2respectively. Whichever donor was considered, IL-1 was
undectable.
As expected, L-NMMA reduced by 81 and 87% the basal
and LPS-stimulated NO production, respectively [Fig. 1(A),
(C)] (P<0·001). As previously described13, the addition
of L-NMMA resulted in a significant enhancement of
LPS-stimulated PGE2 production [Fig. 1(D)] (P<0.001),
suggesting a negative effect of NO on PGE2 synthesis.
Inversely, NAC increased both the basal and LPS-
stimulated NO production [Fig. 1(A),(C)] without significant
effect on PGE2 synthesis (Fig. 1(B),(D)]. When NAC
and L-NMMA were added simultaneously, NO and PGE2
productions varied in the same order of magnitude that
when L-NMMA was added alone (Fig. 1). ACECLO, a
non-steroidal antiinflammatory drug, strongly inhibited
552 M. Mathy-Hartert et al.: ROS on human chondrocytesPGE2 production by both untreated and LPS-treated
chondrocytes but did not significantly modify NO production
(Fig. 1).EFFECTS OF L-NMMA, NAC AND ACECLO ON IL-1, INOS AND COX-2
mRNA EXPRESSION
Real-time RT PCR was performed to quantify the drug
effects on gene expression (Fig. 2). Under basal condition,
both iNOS and COX-2 mRNA were expressed at low levels
while IL-1 mRNA was undetectable. As expected, LPS
(10 g/ml) induced a marked increase of IL-1, iNOS and
COX-2 mRNA levels. After 48 h of incubation, LPS-
stimulated chondrocytes expressed until 19 863±642,
112 600±2326 and 11 283±1138 cDNA copies number per
3 ng of total RNA of IL-1 , iNOS and COX-2 respectively.
L-NMMA (0.5 mM) did not significantly modify LPS-
stimulated gene expressions (Fig. 2). NAC (1 mM)
enhanced IL-1 (P<0.001) and iNOS mRNA levels
(P<0.01) [Fig. 2(A),(B)] without affecting the COX-2 gene
expression [Fig. 2(C)]. Finally, ACECLO (6 · 10−6 M) had a
significant inhibitory effect on IL-1 gene expression
(P<0.01) [Fig. 2(A)] but did not affect COX-2 and iNOS
mRNA levels. These results were confirmed by classical RT
PCR followed by agarose electrophoresis (Fig. 3).EFFECTS OF L-NMMA AND NAC ON COX-2 PROTEIN
To determine the mechanism of action of L-NMMA on
PGE2 production, we studied the COX-2 protein expression
by Western blot analysis (Fig. 4). In the basal condition,
COX-2 protein level was very low and was not modified by
L-NMMA and NAC treatments. An LPS-inducible expres-
sion was observed. L-NMMA and NAC added separately or
in combination had no significant effect on COX-2 protein
level.Fig. 3. Effects of L-NMMA (0.5 mM), NAC (1 mM) and ACECLO (6 · 10−6 M) on gene expressions. RT-PCR products of IL-1, iNOS, COX-2
and -actin were fractionated by electrophoresis through a 1.5% agarose gel and visualized by ethidium bromide staining.Discussion
We have demonstrated that the inhibition of NO2 produc-
tion by L-NMMA was accompanied by an increase of PGE2
production suggesting a negative feedback of NO on PGE2
synthesis. Our results are in accordance with previous
studies showing by the inhibition of NO synthase or the
incubation of cells with NO donors, that NO down-regulated
PGE2 production in cell line murine macrophages23, in rat
peritoneal macrophages11, in human and bovine chondro-
cytes13,14 and in human osteoarthritic cartilage
explants12,14. In contrast, others have reported that NO
enhanced COX-2 activity and PGE2 production in different
cell types8–10. Interestingly, Stadler3 demonstrated a dual
role of L-NMMA on PGE2 production in rabbit chondrocytes
culture. When low or high levels of NO were produced by
cells activated by, respectively, IL-1 alone or by a combi-
nation of IL-1 plus LPS, an inhibition or an enhancement
of the PGE2 production was obtained. Stadler’s study
provides a possible explanation for the discrepancy
reported in the literature about the relation between NO and
PGE2 synthesis, suggesting a biphasic effect of NO accord-
ing to its production level.
Furthermore, we have shown that L-NMMA did not
modify both the COX-2 mRNA level and protein synthesis.
These observations suggested that the overproduction of
PGE2 resulting from the L-NMMA treatment was directly
related to the control of the enzymatic activity of cyclo-
oxygenase. This control could be performed by nitrogen-
derived oxidant molecules that could regulate by tyrosine
nitration and oxidation the cyclo-oxygenase activity. This
mechanism was reported for other enzymes. For example,
manganese superoxide dismutase was inactivated by
ONOO− through a mechanism involving not only nitration
of critical tyrosine residues but also tyrosine oxidation and
subsequent formation of dityrosine24. Roy et al.25 demon-
strated that NO reacts rapidly with ribonucleotide
Osteoarthritis and Cartilage Vol. 10, No. 7 553Fig. 4. Western blot analysis of COX-2 in human chondrocyte extracts. Cells were cultured for 48 h in the absence or the presence of LPS
(10 g/ml). L-NMMA (0.5 mM) or NAC (1 mM) were added at the beginning of culture. The cells were lysed and protein extracts were
analysed by Western blot with a specific antiserum for COX-2. Ovine COX-2 (400 ng) was used as standard.reductase, silencing its electronic paramagnetic resonance
tyrosyl radical signal and inhibiting its enzymatic activity.
COX-2 also produces a tyrosyl radical critical to its catalytic
activity26. In previous studies, we and others have shown
that phorbol myristate acetate, LPS, anoxia–reoxygenation
cycles and several cytokines (IL-1, TNF, IFN), induced
the production of ROS by chondrocytes including O ·2,
H2O2, and ·OH1,2. Furthermore, using RT-PCR, we have
observed that in our experimental conditions chondrocytes
expressed the p22 sub-unit which is a regulatory element of
the NADPH oxidase (data not shown). These data suggest
that ROS, produced intracellularly by LPS-stimulated
chondrocytes, could react with NO to form ONOO−1, which
is presented as a potential enzyme inhibitor. Finally, we can
also suggest that NO or a nitric-oxide derived oxidant
reacts with the phospholipase A2 and inhibits the release of
arachidonic acid, the subtrate of cyclo-oxygenases. Never-
theless, Kosonen and colleagues27 did not confirm this
latter hypothesis, showing that the addition of exogenous
arachidonic acid to endothelial cell cultures did not alter the
inhibitory effect of NO donors on prostacyclin production,
suggesting that phospholipases are not the target of NO
action. On the other hand, Martinez et al.28 reported an
increase of PLA2 activity in the membrane fraction of
murine peritoneal macrophages submitted to SIN-1, a
NO/O ·2 donor. This stimulating effect was markedly inhib-
ited in the presence of SOD, while L-NMMA had no effect.
In our study, we have also demonstrated that NAC
increased NO synthesis and iNOS gene expression but
was without effect on PGE2 production and COX-2 mRNA
levels. These findings corroborate the results of Jiang and
Brecher29 demonstrating that N-acetyl-cysteine facilitated
IL-1-induced nitric oxide synthase (iNOS) expression in
rat vascular smooth muscles cells through a reduction/
oxidation-related mechanism involving potentiation of
cytokine activation of the p44/42 MAPK signaling pathway.
Another explanation was given by Huang and col-
leagues30, who reported that ascorbic acid enhanced
endothelial nitric-oxide synthase activity by increasingintracellular tetrahydrobiopterin BH4 content. Concerning
the regulation of COX activity by antioxidants, our study
was in disagreement with other studies which reported that
known antioxidants, such as butylated hydroxyanisol or
diphenylamine, were also potent inhibitors of arachidonic
acid metabolism31.
ACECLO is a NSAID of the phenylacetic acid class,
commonly used in the treatment of arthritis. Interestingly,
the mechanism of action of ACECLO is multifactorial.
Indeed, this NSAID acts not only by inhibiting preferentially
the COX-2 activity but also by decreasing proinflammatory
cytokines synthesis and by scavenging reactive oxygen
species32. At 1 · 10−5 M, ACECLO decreased luminol-
enhanced chemiluminescence generated by PMA-
activated neutrophils and accelerated the decomposition of
ONOO−, suggesting a potential capacity of this drug to
scavenge ONOO−. In contrast, and by comparison with
other classical NSAID, ACECLO did not reduced lipid
peroxydation induced by Fe2+/ascorbate system and did
not significantly reduced HOCl induced chemilumines-
cence. Furthermore, we have recently demonstrated that,
at therapeutic concentration (ranged among 6 to 10
10−6 M) ACECLO did not react with ·OH or O−2 (submitted
data). Taken together, these findings demonstrated that
ACECLO preferentially inhibited ONOO− but not O−2 , ·OH
or HOCl. Considering these particular antioxidant proper-
ties, we have tested this drug on the expression of COX-2,
IL-1 and iNOS genes, and on the synthesis of PGE2 and
NO. Interestingly, ACECLO fully blocked PGE2 synthesis
without affecting COX-2 gene expression. Furthermore, we
have previously reported that ACECLO strongly inhibited
COX-2 activity (IC50=8 · 10−7 M) in the whole blood test
but showed an anecdotal effect on purified cyclo-
oxygenases33. These observations suggested that ACE-
CLO probably exerts its inhibitory action on PGE2 synthesis
at the post-transcriptional level but not by a direct interac-
tion with the catalytic site of COX.
Taken together, these data clearly demonstrate that NO
down-regulates PGE synthesis at the post-transcriptional2
554 M. Mathy-Hartert et al.: ROS on human chondrocyteslevel and that antioxidants, such as N-acetyl-cysteine,
increase NO synthase activity and expression. These find-
ings suggest that antioxidant therapy could have contradic-
tory effects as a function of the molecule administered,
especially the oxygen radical targeted. To block NO could
result in an increase of PGE2 production, which was clearly
identified as an inflammatory and catabolic factor. Increas-
ing the antioxidant status of the cell could induce an
overproduction of NO.References
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